



Zylox-Tonbridge (2190.HK)

2024 Interim Results Presentation

August 2024

This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase securities of Zylox-Tonbridge Medical Technology Co., Ltd. (the "Company").

This presentation does not constitute or contain an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and neither this presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Securities may not be offered or sold in the United States absent registration or an available exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). All the information in this presentation has been provided by the Company and has not been independently verified by its advisers or any of their respective affiliates or associates (collectively, "advisers"). No representation, warranty or undertaking, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries or by its advisers or representatives as to the fairness, accuracy, completeness or correctness of, this presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

This presentation is not intended to provide the basis for evaluating, and should not be considered a recommendation with respect to, any transaction or other matter. Any analyses included herein are not and do not purport to be appraisals of the assets or business of the Company or any of its subsidiaries or affiliates. Nothing in this presentation should be construed as regulatory, valuation, legal, tax, accounting or investment advice. Before you enter into any transaction, you should ensure that you will be responsible for conducting your own due diligence investigation with respect to the Company and fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. Any decision to purchase securities of the Company in any public or private offering should be made solely on the basis of the prospectus and/or international offering circular to be prepared by the Company in relation to any such contemplated offering together with any supplementary pricing information. This presentation contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of section 2(1) Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) (the "Companies Ordinance"), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "Securities and Futures Ordinance") or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.

The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects", "believes" and "anticipates" and words of similar import. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisers or representatives are unaware. These forward looking statements are not a guarantee of future performance. Against the background of these uncertainties, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation is confidential and must not be copied, reproduced, distributed or passed (in whole or in part) to any other person at any time without the prior written consent of the Company or its advisers.

By accepting this presentation, the recipient has agreed, upon request, to return promptly all material received from the Company or its advisers (including this presentation) without retaining any copies. In furnishing this presentation, the Company and its advisers or representatives undertake no obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies therein which may become apparent.

By reading and attending this presentation, you agree to be bound by the foregoing restrictions, and you shall be deemed to have represented to us that you (and any customers you represent) are either (a) a qualified institutional buyer (as defined in Rule 144A under the U.S. Securities Act) or (b) outside the United States (within the meaning of Regulation S under the U.S. Securities Act). You also represent that you (and any customers you represent) are "professional investors" described in Part I of Schedule 1 to the Securities and Futures Ordinance and any subsidiary legislation thereunder (including but not limited to the Securities and Futures (Professional Investor) Rules (Chapter 571D of the Laws of Hong Kong)).

The distribution of this presentation in any jurisdiction may be restricted by law and persons in possession of this presentation should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Any prospective purchaser interested in buying securities of or evaluating the Company is recommended to seek its own independent legal, tax, financial and other professional advice.

Financial

Revenue → 366 million RMB
+ 59.0% YOY Growth

Overseas revenue → 11.49 million RMB
+ 84.2% YOY Growth

Expenses Ratio → Selling and Distribution Expenses : 22.0%
(FY 20223: 31.0%)

R&D Expenses : 28.0%
(FY 2023 : 50.0%)

Unadjusted Net Profit → Profit 68.87 million RMB
(FY 2023 :
Loss 78.73million RMB)

Sales

Industry leader of promoting innovative ideas and techniques

- The sales network covers more than 3,000 hospitals, more than 500 secondary distributors
- Ongoing industry benchmarking activities
- VBPs Implementation

Create new impetus for the growth of our international business

- Overseas sales revenue amounted to 11.49 million RMB, 84.2% YOY Growth
- Commercialized in 22 countries/regions
- Accelerating Overseas Layout

R&D

8 Number of NMPA registration approvals obtained in mid-2024

- The first Flow Diverter with distal closure design in China
- The first self-developed Suture-Mediated Closure system in China
- Proximal beveled port, tapered taper and integrated structure of the Peripheral Venous Stent System
- Other innovative products

10+ Number of clinical trials conducted simultaneously in the first half of 2024

5 Number of products in the registration phase



Financial Highlights

- High revenue growth, turn loses into profits

Commercialization of High-quality Products Triggered Rapid Revenue Growth




Rapid Revenue Growth in 2022H1-2024H1

(in 000' RMB)

Gross Profit Margin: ■ 75.6% ■ 74.2% ■ 71.3%


2022H1-2024H1 CAGR: **55%**



Overseas Sales Rise Sharply in 2022H1-2024H1


(in 000' RMB)

2022H1-2024H1 CAGR: **105%**



Revenue of Neurovascular Products

(in 000' RMB)




Main Source of Revenue



Thrombite Clot Retriever Device



SilverSnake Intracranial Support Catheter



Kylin Flow Diverter



Phoenix Detachable Coil System



Baiju Intracranial Balloon Catheter

Other Launched Products



BeidouSS® Neurovascular Guidewire



Dayu Balloon Guiding Catheter (BGC)




SilverSnake Distal Access Catheter

Revenue of Peripheral-vascular Products

(in 000' RMB)

% of Revenue :



■ Peripheral-vascular Interventional Devices

Main Source of Revenue

| | | | | | |
|--|---|--|--|--|--|
| | Drug Coated PTA Balloon Catheter | | Retrievable Inferior Vena Cava Filter | | Snare Retrieval Kit for IVC Filter |
| | PTA Balloon Catheter | | High Pressure PTA Balloon Catheter | | Endovenous Radiofrequency Ablation (RFA) Catheter |


Other Launched Products

| | | | | | | | |
|--|---|--|---|--|---|--|---|
| | Penguin Peripheral Venous Stent System | | Unicorn Suture-mediated Closure System | | Phoenix Peripheral Detachable Fibrous Coil Embolization System | | Peripheral Stent System (Overseas) |
|--|---|--|---|--|---|--|---|

Increased Operational Efficiency in Line with Business Development


Selling and Distribution Expenses

% of Revenue




R&D Expenses

% of Revenue



Administrative Expenses


% of Revenue



With the Continuous Improvement of Sales Scale and Operational Efficiency, the Trend of Profits Emerged

Other Non-operating Income and Expenses

(in 000' RMB)




Notes:

1. Primarily attributable to a decrease in bank interest income in the Reporting Period

2. Primarily due to net fair value losses from FVPL

Unadjusted Net Profit / (Loss)


(in 000' RMB)



| | | | |
|------------------------------|---------|--------|--------|
| Listing expenses | 22,733 | — | — |
| Share-based compensation | 87,678 | 85,767 | 9,306 |
| Adjusted Net Profit / (Loss) | -25,877 | 7,033 | 78,171 |


Cash From Operating Activities

(in 000' RMB)




2024H1 Cash Status

(in 000' RMB)



Trade Receivables Turnover

(Turnover Days)



Notes:

1. Total funds at the beginning and end of the period include cash and cash equivalents, term deposits, and financial assets at fair value through profit or loss.
2. We reverse cash flows from financing activities by the amount of principal and interest related to lease payments, and increase the operating cash flows by the same amount.
3. Others referring to exchange gains on cash and cash equivalents.



Sales and Marketing


- Extensive Sales Network and Rapid Commercialization Progress

Deeply Cultivate the Domestic Market, Continuing to Strengthen the Channel Advantage to Build an Extensive Sales Network

Distributors Across the Country




Number of Secondary Distributors Nationwide



Extensive sales network covers more than **3,000** Hospitals in **31** Provinces

Rapid Commercialization Capabilities

Numbers of Provincial Procurement Platforms that Newly Launched Products are Included into in Last One Year (Data as of August 9, 2024)



Continued approval of more products , maintaining a rapid pace of hospital admissions for future long-term growth rate

Notes:

1. Approval Time: Neurovascular Products: Introducer Sheath 2023.7, Clot Retriever Device II 2023.10, Radial Access Distal Support Catheter 2023.11, Embolic Protection System 2024.3, Flow Diverter 2024.3, Intracranial PTA Balloon Catheter II 2024.2, Microcatheter for Intracranial Stent 2023.7 Mechanical Detachable Coil II 2024.1. Peripheral-vascular Products: Peripheral Venous Stent System 2024.1, Peripheral Detachable Embolization Coils 2023.12, Infusion Catheter 2023.9, Tapered PTA Balloon Catheter 2024.1, Second Generation DCB 2024.1, Long Balloon Catheter 2024.3, PTA Scoring Balloon Catheter 2024.3, Suture-mediated Closure System 2024.5.



Doctor training support activities:

- Covered **5** stroke centers in Changzhou, Beijing, Zhengzhou, Chenzhou and Kunming, including live surgery broadcast events, devices in vitro demonstration, fun running activities, etc. Accelerates the listing & training of BADDASS and R-DAS training center.
- Relying on a large center of regional influence, the trainees radiate across the country.




Domestic and overseas meetings and panels:

- Held a total of **98** offline meetings (**16+** per month), **9** online meetings, including **6** international linkage activities to create a high-end brand.
- Co-organizes national conferences in the industry: WSIC, CFCVD2024&NICME, Alice, etc.




In-depth case studies newsletters & live surgery broadcast events:

- Published **41** cases (**7** cases / month); Covered ischemic \ hemorrhagic \ intracranial stenosis topics and products.
- Continue to promote the “Shenjie Guochao series of live surgery broadcast events.
- Theme-based activities were held for specific procedures: Feng Ming Lin Out, Story Exchange, Tong Da Zhi Yuan, BADDASS Webinar.
- Special events were held for young physicians: online forum for building stroke centers in primary hospitals.



| | Kylin Flow Diverter | Pipeline-PREMIER |
|---|---------------------|------------------|
| Complete Occlusion Rate of Aneurysms at 12-month Post-procedure | 88.15% | 81.88% |
| Immediate Procedural Success Rate | 100% | 99.29% |
| Incidence of New-onset Stroke in the Territory Supplied by the Treated Artery or Neurologic Death in 12 Months Post-procedure | 0.70% | 2.17% |
| Incidence of Any Stroke in 12 months Post-procedure | 2.11% | 7.80% |
| Incidence of Parent Artery Stenosis (>50%) or Occlusion in 12 Months Post-procedure | 2.21% | 2.90% |
| All-cause Mortality in 12 Months Post-procedure | 0% | 0.71% |



Participated in **10+** professional academic conferences, Conducted an international live surgery broadcast at Alice Neurointerventional Physician Forum

Complete Occlusion Rate of Aneurysms at 12-month Post-procedure **88.15%**

Numbers of Provincial Procurement Platforms **21**

China's first Flow Diverter with distal closure design

Notes:
 1. The 21st China Forum on Cerebrovascular Diseases (CFCVD) was held from April 26th to 28th, 2024. During the conference, Professor Liu Jianmin from Changhai Hospital in Shanghai made a significant announcement regarding the pre-market clinical data of the Kylin Flow Diverter.
 2. Pipeline Premier's data sources: Food and Drug Administration. PMAP100018/S015: FDA Summary of Safety and Effectiveness Data- Pipeline™ Flex Embolization Device. 2018. and Hanel RA, Kallmes DF, Lopes DK, et al. Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results. J Neurointerv Surg 2020; 12(1): 62-6.

Creation Of Brand 「JINGLUN」 For Peripheral Venous Communication



Creation Of Brand 「YUANXING」 For Peripheral Artery Communication



Active Participation in Professional Academic Conferences



VINNOVA 2024



CAVS 2024



SJVF 2024



CPEC 2024




CVC 2024



SEC 2024

Peripheral-vascular Launched Key Product – Penguin Peripheral Venous Stent System



Active Participation in **14+** Professional Academic Conferences

The patency rate of target vessels reached **100%** at 12 months postoperatively

Numbers of Provincial Procurement Platforms **26**

Proximal beveled port, tapered taper and integrated structure of the Peripheral Venous Stent System

为患者 恒创新/Innovation for quality life

Peripheral-vascular Launched Key Product – Unicorn Suture-mediated Closure System



According to the forecast, the annual number vascular closure procedures in China was about **0.28 million** and it is expected to reach **3.78 million** by 2030, with a CAGR of **26.9%**.

Effectively **simplify** and **accelerate** the process of vascular closure, improving the **safety** and **success** rate of procedures

Expanded suture range of **5F–22F**, which is compatible with large bore sutures of **8F or above**

The first self-developed suture-mediated closure system in China

Notes:1. Source: Frost & Sullivan analysis

Products Approved in Overseas Markets

Neurovascular


| Product | Approved Region |
|----------------------------------|--|
| Thrombite Clot Retriever Device | EU and 9 countries including U.K., Turkey, South Africa, Argentina, Russia, etc. |
| Aspiration Catheter | EU and 9 countries including U.K., Turkey, South Africa, Argentina, Russia, etc. |
| Microcatheter for Clot Retriever | EU and 7 countries including U.K., South Africa, Argentina, etc. |
| Gekko Detachable Coil System | 2 countries including Russia, Dominican Republic |

Peripheral-vascular

| | |
|---|--|
| ZENfluxion Peripheral Drug Coated Balloon Catheter | EU and 10 countries including Turkey, Argentina, U.K., UAE, etc. |
| ZENFlow PTA Balloon Catheter | EU and 13 countries including Turkey, Argentina, U.K., UAE, etc. |
| ZENFlow PTA High Pressure Balloon Catheter | EU and 11 countries including Turkey, Argentina, U.K., UAE, etc. |
| ZENFlex Peripheral Stent System | EU and 13 countries including Argentina, U.K., UAE, etc. |
| ZENFLEX Pro Peripheral Drug-Eluting Stent System | EU and 12 countries including Argentina, U.K., UAE, etc. |
| ZENFlow Tiger PTA Balloon Catheter Large Diameter | 3 countries including Brazil, Estonia, Latvia |
| ZENFLOW Second Generation PTA Balloon Catheter | Brazil |
| ZENFLOW HP PTA Second Generation High Pressure Balloon Catheter | Brazil |

Commercialized in 22 Countries/Regions

➤ Accelerate overseas layout, centering on Europe, further expanding into South America and Asia (mainly Russia and Korea)



Three-Year Results of Turkish Clinical Study of Thrombite thrombectomy device Released

- The study was a retrospective analysis of **525** patients who were included in the Turkish Interventional Neurology database and who had mechanical thrombectomy with the Thrombite device as the first choice between January 2020 and January 2023.
- The results of the study showed that **48.2%** (mTICI 2b/3) and **33.9%** (mTICI 2c/3) were the first-pass recanalization rates. In the end, 82.1% of patients had effective recanalization (mTICI 2b/3). In the “first-pass” subgroup, the favorable functional result (modified Rankin Scale 0–2) was **51.8%**, while it was **41.6%** for the entire patient population.
- It is possible to utilize the Thrombite™ thrombectomy device as the **first-line option** for LVO stroke thrombectomy, given the high rates of first-pass and final recanalization observed in the study.
- Since obtaining CE certification in 2020, the Thrombite thrombectomy device has been recognized and welcomed by local physicians for its innovative product design and high-quality product standards.

Notes:

1. Professor Erdem Gurkas from the University of Health Sciences in Turkey and Professor Çetin Kürşad Akpınar from Samsun Training and Research Hospital, along with other researchers, conducted a retrospective analysis on cases using Thrombite thrombectomy device from 2020 to 2023. The results were published in May 2024.

1
Three years’ interventional neurology experience in Turkey with the Thrombite thrombectomy device in large vessel occlusion in the anterior circulation: safety, efficacy, and clinical outcome

Çetin Kürşad Akpınar¹, Erdem Gurkas², Atilla Ozcan Ozdemir³, Hasan Doğan^{4*}, Ayşenur Önalın², Serhan Yıldırım⁴, Zülfikar Memiş⁵, Emrah Aytaç⁶, Bilgehan Atılın Acar⁷, Muhammed Nur Ögün⁸, Özlem Aykaç³, Zehra Uysal Kocabaş³, Türkan Acar⁷, Halil Alper Eryılmaz⁷ and Berkhan Topaktaş⁹

¹Samsun Training and Research Hospital, Stroke Center, Department of Neurology, Samsun University, Samsun, Türkiye; ²Kartal Dr. Lütfi Kırdar City Hospital, Stroke Center, Department of Neurology, Health Sciences University, İstanbul, Türkiye; ³Eskişehir Osmangazi University Hospital, Stroke Center, Department of Neurology, Eskişehir, Türkiye; ⁴Kocaeli City Hospital, Stroke Center, Department of Neurology, Kocaeli, Türkiye; ⁵Haseki Training and Research Hospital, Türkiye, Department of Neurology, Health Sciences University, İstanbul, Türkiye; ⁶Fırat University Hospital, Stroke Center, Department of Neurology, Elazığ, Türkiye; ⁷Sakarya University Hospital, Stroke Center, Department of Neurology, Sakarya, Türkiye; ⁸Abant İzzet Baysal University Hospital, Stroke Center, Department of Neurology, Bolu, Türkiye; ⁹

TABLE 2 Details of endovascular treatment.

| Procedural characteristics | |
|--|---------------|
| Onset to groin puncture (min) | 215 (155–325) |
| Groin puncture to successful recanalization (min) | 29 (15–65) |
| Balloon guide catheter, n (%) | 26 (5) |
| Combined aspiration–stent retriever technique, n (%) | 479 (94.9) |
| Reperfusion outcome, n (%) | |
| Successful first-pass recanalization (mTICI 2b/3), n (%) | 243 (48.1) |
| Excellent first-pass recanalization (mTICI 2c/3), n (%) | 171 (33.9) |
| Successful final recanalization (mTICI 2b/3), n (%) | 443 (87.7) |
| mTICI 3, n (%) | 109 (21.6) |
| mTICI 2c, n (%) | 159 (31.5) |
| mTICI 2b, n (%) | 175 (34.7) |
| Rescue treatment | 39 (7.7) |

Values are mean (SD), median (IQR), or n (%) as appropriate. IQR, interquartile range; mTICI, modified treatment in cerebral infarction; SD, standard deviation.

TABLE 1 Baseline characteristics of patients.


| Characteristics (n: 505) | n (%) |
|--|-------------|
| Age (mean ± SD) | 68.6 ± 11.7 |
| Gender (Male) | 245 (48.5) |
| NIHSS score on admission, median (IQR) | 13 (11–18) |
| CT ASPECT score, median (IQR) | 7 (6–9) |
| Vascular risk factors, n (%) | |
| Hypertension | 430 (85) |
| Diabetes mellitus | 96 (19) |
| Atrial fibrillation | 162 (32) |
| Coronary artery disease | 56 (11) |
| Current smoking | 126 (25) |
| Alcoholism | 25 (5) |
| Hyperlipidemia | 66 (13) |
| Stroke etiology, n (%) | |
| Cardioembolism | 278 (55) |
| Large artery atherosclerotic disease | 49 (9.8) |
| Carotid dissection | 11 (2.2) |
| Unknown etiology | 167 (33) |
| Intravenous rtPA, n (%) | 195 (38.6) |
| Occlusion site, n (%) | |
| MCA M1 occlusion | 213 (42.2) |
| MCA M2 occlusion | 127 (25.1) |
| Tandem ICA–MCA occlusion | 55 (10.9) |
| Carotid I, L, T occlusion | 101 (20) |
| Anterior cerebral artery A1 occlusion | 9 (1.8) |

Values are mean (SD), median (IQR), or n (%) as appropriate. ASPECT, Alberta Stroke Program Early CT Score for MCA territory stroke; CT, computed tomography; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale.

| Radiological and clinical outcomes | |
|--------------------------------------|------------|
| Embolization to new territory, n (%) | 11 (2.2) |
| Intracranial hemorrhage, n (%) | |
| Hemorrhagic infarction 1 | 39 (7.7) |
| Hemorrhagic infarction 2 | 61 (12.1) |
| Parenchymal hematoma 1 | 33 (6.5) |
| Parenchymal hematoma 2 | 23 (4.6) |
| Subarachnoid hemorrhage | 9 (1.8) |
| Procedure-related dissection, n (%) | 8 (1.5) |
| Vessel perforation | - |
| Outcome, n (%) | |
| Modified Rankin Scale 0–2 | 262 (41.6) |
| Modified Rankin Scale 3–6 | 243 (58.4) |
| All-cause mortality at 90 days | 84 (16.6) |

Values are mean (SD), median (IQR), or n (%) as appropriate. IQR, interquartile range; SD, standard deviation.

Leveraging a differentiated and comprehensive product portfolio, Embraced VBPs and increased products' market penetration






R&D



- Advance R&D with great efficiency steadily and innovatively

| |
|---|
| <p>Intracranial Ischemic Stroke Procedure Volume: 110,000 units (2023)</p> <p>BADDASS : Clot Retriever Device + Support Catheter + BGC Bolus removal and suction: Clot Retriever Device + Aspiration Catheter</p> |
| <p>Intracranial Hemorrhagic Stroke Procedure Volume: 110,000 units (2023)</p> <p>Coil + Flow Diverter + Intracranial Stent</p> |
| <p>Intracranial Stenosis Procedure Volume: 65,000 units (2023)</p> <p>Intracranial PTA balloon catheter (Rx) + Intracranial Drug Coated Balloon Catheter + Drug Coated Self-expandable Intracranial Stent</p> |
| <p>Carotid Artery Stenosis Procedure Volume: 70,000 units (2023)</p> <p>Carotid Rx PTA Balloon Catheter + Embolic Protection System + Carotid Stent</p> |
| <p>Intracranial Access Procedure Volume: 355,000 units (2023)</p> <p>Innovative Surgical Pathways : Radial Access Distal Support Catheter 、 Introducer Sheath</p> <p>Other Access: Microcatheter for Coiling 、 Microcatheter for Intracranial Stent 、 Microcatheter for Clot Retriever 、 Neurovascular Guidewire et al.</p> |



| |
|--|
| <p>Peripheral Artery Disease Procedure Volume: 170,000 units (2023)</p> <p>PTA Balloon (Normal 、 High Pressure) + DCB + IVL +Cutting Ballon</p> |
| <p>Peripheral Venous Disease VTE Prevention and Treatment (Filter placement, venous thrombus removal, etc.) Procedure Volume: 200,000 units (2023)</p> <p>Retrievable Inferior Vena Cava Filter + Snare Retrieval Kit for IVC Filter + Peripheral Thrombectomy System + Infusion Catheter</p> <p>Iliac vein compression syndrome (IVCS) Procedure Volume: 50,000~60,000 units (2023)</p> <p>Peripheral Venous Stent System</p> |
| <p>Varicose Veins Procedure Volume: 80,000 units (2023)</p> <p>Endovenous Radiofrequency Ablation (RFA) Catheter+ Radiofrequency Generator</p> |
| <p>Vascular Closure Procedure Volume: 约 350,000 units (2023)</p> <p>Suture-mediated Closure System + Vascular Closure System</p> |
| <p>Others</p> <p>Hemodialysis Access : High Pressure Balloon Catheter Peripheral Embolization Intervention : Peripheral Detachable Embolization Coils Aortic Intervention : Thoracic Aorta Stent Graft System</p> |


Note: The above data comes from market research organization forecast.

Neurovascular Interventional Portfolio – 29 Products




| | 23 Approved Products | | | | 6 Products | | |
|--|---|--|--|--|--|--|--------------------------|
| | 2020 2 Approved | 2021-2022 9 Approved | 2023 8 Approved | 2024 4 Approved | 2025 2 Approved | 2026 3 Approved | 2027 1 Approved |
| Intracranial Ischemic Stroke | Thrombite Clot Retriever Device (CRD) | Balloon Guiding Catheter (BGC) Microcatheter for Clot Retriever Aspiration Pump System | Aspiration Catheter Clot Retriever Device II | | | | |
| Intracranial Stenosis | | Second Generation Intracranial PTA balloon catheter (Rx) | Microcatheter for Intracranial Stent | Second Generation Intracranial PTA balloon catheter (Rx) | Intracranial Drug Coated Balloon Catheter | Drug Coated Self-expandable Intracranial Stent Intracranial Stent | Vertebral Artery DES |
| Intracranial Hemorrhagic Stroke | | Neurovascular Embolization Coil Microcatheter for Coiling | Microcatheter for Flow Diverter | Mechanical Detachable Coil II Flow Diverter | Embolization Assist Stent (Self-expandable Intracranial Stent) | | |
| Intracranial Access | Intracranial Support Catheter | Distal Access Catheter Standard Intracranial Support Catheter | Neurovascular Guidewire Intermediate Catheter Radial Access Distal Support Catheter Introducer Sheath | | | | |
| Carotid Artery Stenosis | | Carotid Rx PTA Balloon Catheter | | Emboic Protection System | | Carotid Stent | |

Embolization Assist Stent




- **Indications**
 - ✓ Intracranial Hemorrhagic Stroke. It is often used in combination with a coil for the surgical treatment of complex intracranial aneurysms and wide-necked aneurysms.
- **Target Market**
 - ✓ Stroke epidemiology shows, there are 4 million new cases of stroke each year, of which hemorrhagic stroke accounts for about 20%, and wide-necked aneurysms clinically account for about 40% of the proportion of aneurysms.¹
- **Product Characteristics**
 - ✓ **Through-body visualization:** Full-body radiopacity with nickel-titanium wrapped in platinum, making each filament visible under imaging. It has three radiopaque markers at both the proximal and distal ends, allowing surgeons to better assess the stent's deployment status.
 - ✓ **Stent's diverse filament count:** Lightweight design, ease of opening and adherence ensure smooth deployment in various vessels. The super-elastic nickel-titanium material adapts well to tortuous vessels.
 - ✓ **Smooth push:** The delivery system features release and retrieval radiopaque markers, ensuring the distal end of the microcatheter does not exceed the retrieval marker.
 - ✓ **Compatible with more indications:** Its high metal coverage maintains collateral vessel circulation.

Drug Coated Self-expandable Intracranial Stent



Self-expandable Intracranial Stent



Rapamycin




















- **Indications**
 - ✓ Intracranial Stenosis
- **Target Market**
 - ✓ According to the Frost & Sullivan Report, 30% to 50% of ischemic stroke cases are related to intracranial stenosis. The number of patients with intracranial stenosis in China amounted to 17.3 million in 2019, and is estimated to further increase to 27.9 million in 2030.
- **Product Characteristics**
 - ✓ **Drug performance :** Designed with appropriate drug loading capacity for thrombosis reduction, which can maintain the effective concentration of drug in the tissues appropriately, while reducing tissue cytotoxicity.
 - ✓ **Stent performance:** Adopts a unique design of mesh and stent ribs, which ensures even stress and strain distribution, providing sufficient radial support for excellent wall apposition.
 - ✓ **Delivery system performance:** Equipped with a multi-stage stiffness distribution, which is both supportive and flexible with a higher delivery ratio.

Note:

1. The literature "Preliminary Application of Neuroform Atlas Embolization Assist Stent for the Treatment wide-necked aneurysms," states that wide-necked aneurysms account for >40% of intracranial aneurysms .

Peripheral-Vascular Interventional and Vascular Closure Devices Portfolio – 34 Products



| | 21 Approved Products | | | | 12 Products | | | |
|----------------------------------|--|--|---|---|--|---|---|---|
| | 2020 4 Approved | 2021-2022 4 Approved | 2023 9 Approved | 2024 4 Approved | 2025 5 Products | 2026 4 Products | 2027 2 Products | 2028 1 Product |
| Arteria |  <p>UltraFree Drug Coated PTA Balloon Catheter (DCB) PTA Balloon Catheter</p> |  <p>Endovascular Snare</p> |  <p>Second Generation PTA Balloon Catheter Tapered PTA Balloon Catheter Second Generation Drug Coated PTA Balloon Catheter (DCB II)</p> |  <p>Long Balloon Catheter PTA Scoring Balloon Catheter</p> |  <p>Pantheris 1 LightBox 3 1 Drug Coated PTA Balloon Catheter-BTK</p> |  <p>Tigereye ST 1 IVL System Sawtooth Removal Balloon Catheter</p> |  <p>Balloon Expandable Covered Stent Multi-spot Stent System</p> |  <p>Peripheral Drug-eluting Stent System</p> |
| Venous |  <p>Snare Retrieval Kit for IVC Filter</p> |  <p>Retrievable Inferior Vena Cava Filter Endovenous Radiofrequency Ablation (RFA) Catheter</p> |  <p>Radiofrequency Generator Infusion Catheter</p> |  <p>Peripheral Venous Stent System</p> |  <p>Peripheral Thrombectomy System</p> | | | |
| Hemodialysis Access |  <p>PTA High Pressure Balloon Catheter</p> | |  <p>PTA Second Generation High Pressure Balloon Catheter</p> | | |  <p>Ultra High Pressure Balloon Catheter</p> | | |
| Other Peripheral-Vascular | | |  <p>TIPS Access Set Peripheral Detachable Embolization Coils Peripheral Hydrophilic Guidewires Series</p> | | | | | |
| Vascular Closure Devices | | | |  <p>Suture-mediated Closure System</p> |  <p>Vascular Closure System</p> | | | |

Notes:1.Pantheris OCT-guided Peripheral-vascular Atherectomy Catheter Series, LightBox 3 OCT Imaging Consoles and Tigereye ST OCT-guided Peripheralvascular Chronic Total Occlusion-crossing Catheter are products of Avinger, a company in the United States, which are represented by our company.

Multi-spot Stent System



- **Indications**
 - ✓ Balloon expanded femoral and popliteal artery dissection
- **Product Characteristics**
 - ✓ **Refined design:** Each stent is designed with a short-stent double-layer open-ring structure, with an anti-precession snap at one end and multiple visualization markers in the center.
 - ✓ **Optimized radial support design:** Can be applied to a wide range of vessel sizes and different anatomical configurations. It causes less irritation to the vessel, reducing the possibility of intimal hyperplasia.
 - ✓ **Not commercialized products in China yet.**

OCT-guided Peripheral-Vascular Targeted Atherectomy Catheter-Avinger Series



- **Indications**
 - ✓ Directional atherectomy, Lower extremity arterial stenosis
- **Product Characteristics**
 - ✓ **The world's first and only directional atherectomy system with real-time imaging capabilities including OCT.**
 - ✓ **Excellent vascular reducing effect and safety:** Using three-dimensional visual guidance, allowing physicians to see real-time intravascular images. It facilitates easy operation, precise control of the cutting direction, and more efficient navigation to thoroughly remove plaque.
 - ✓ The vascular reduction device can be used in conjunction with several of our products for the treatment to achieve synergistic effects.

Balloon Expandable Covered Stent



- **Indications**
 - ✓ Stenotic and/or occlusive lesions in the common iliac arteries and external iliac arteries
- **Product Characteristics**
 - ✓ **Material and process:** Cobalt chromium alloy tubing material for the main body of the stent; ePTFE coating with high expansion ratio and advanced process to ensure the long-term safety of stent implantation in the human body.
 - ✓ **Special design:** Small delivery diameter, precise dilatation performance and special anti-falling design, with a variety of diameter sizes, which can be adapted to more complex lesions.
 - ✓ Has been recommended as the preferred device for the treatment of lower extremity TASC C/D lesions by a number of domestic and international clinical guidelines.

归创通桥产业园

Prospects



Optimize product portfolio and accelerate innovation based on clinical needs

- Optimize product portfolio by exploring clinical needs
- Continuously enhancing platform advantages and improving R&D efficiency
- Strengthen investment in innovative products and balance medium - and long-term development



Continuously improve operational efficiency and profitability

- Relying on independent research and development technology platform, continuously accumulating professional manufacturing knowledge and consolidating proprietary advanced productivity.
- Actively embracing collective procurement to accelerate product entry and sales volume, and ultimately improve overall profitability.



Continued expansion of product market share based on solid commercialization capabilities

- Provide the market with differentiated technical features and a comprehensive product portfolio
- Gain market share through professional academic education and product strengths




Further expansion into international markets

- Increased overseas registrations, including South America and Pan-Asia region
- Further expansion of the European team and strengthening of relationships with local doctors and distributors



Become China's Leading Minimally Invasive Medical Device Platform



Thank you

**Please refer to 2024 Interim Results
Announcement for further information**
[Click to download the 2024 Interim Results
Announcement](#)

Financial Reports

Consolidated Statements of Profit or Loss



Year ended December 31

Six months ended June 30

| RMB'000 | 2021 % of Revenue | 2022 % of Revenue | 2023 % of Revenue | 2023 % of Revenue | 2024 % of Revenue |
|---|-------------------|-------------------|-------------------|-------------------|-------------------|
| Revenue | 177,912 | 334,090 | 527,754 | 230,131 | 365,990 |
| Cost of sales | -46,031 | -81,421 | -142,766 | -59,485 | -105,077 |
| Gross Profit | 131,881 | 252,669 | 384,988 | 170,646 | 260,913 |
| Selling and distribution expenses | -95,269 | -140,137 | -163,827 | -74,939 | -79,982 |
| Administrative expenses | -100,599 | -109,337 | -114,088 | -50,358 | -43,591 |
| Research and development expenses | -168,100 | -233,461 | -261,013 | -130,806 | -101,542 |
| Other income | 15,286 | 12,165 | 14,851 | 5,198 | 10,642 |
| Other expenses | -712 | -1,339 | -1,599 | -620 | -614 |
| Other gains/(losses) - net | 5,058 | 11,066 | -15,820 | 6,752 | -9,211 |
| Net impairment losses on financial assets | -21 | -24 | -15 | -6 | -16 |
| Operating loss | -212,476 | -208,398 | -156,523 | -74,133 | 36,599 |
| Finance income | 13,094 | 95,565 | 79,040 | 39,256 | 34,579 |
| Finance costs | -307 | -722 | -1,251 | -346 | -1,215 |
| Finance income/(costs) – net | 12,787 | 94,843 | 77,789 | 38,910 | 33,364 |
| Share of net loss of an associate accounted for using the equity method | – | – | – | – | -1,098 |
| Profit/(Loss) before income tax | -199,689 | -113,555 | -78,734 | -35,223 | 68,865 |
| Income tax expense | – | – | – | -291 | – |
| Profit/(Loss) for the year | -199,689 | -113,555 | -78,734 | -35,514 | 68,865 |
| Profit/(Loss) attributable to equity holders of the Company | -199,689 | -113,555 | -78,734 | -35,514 | 68,865 |

Other References:

| | | | | | |
|-------------------------------------|-----------------|-------------|----------------|-----------|---------------|
| Listing expenses | 22,733 | - | - | - | - |
| Share-based compensation | 76,211 | 43% | 87,678 | 16% | 9,306 |
| Adjusted Net Profit / (Loss) | -100,745 | -57% | -25,877 | 1% | 78,171 |

| <i>RMB'000</i> | Year ended December 31 | | | Six months ended |
|---|------------------------|------------------|------------------|------------------|
| | 2021 | 2022 | 2023 | June 30 |
| | | | | 2024 |
| Non-current assets | | | | |
| Property, plant and equipment | 178,270 | 290,243 | 538,540 | 615,262 |
| Right-of-use assets | 34,115 | 48,136 | 39,820 | 39,742 |
| Intangible assets | 4,889 | 9,637 | 9,686 | 34,721 |
| Prepayments and other receivables | 6,804 | 10,645 | 4,278 | 2,989 |
| Financial assets at fair value through profit or loss | 0 | 43,361 | 33,310 | 116,585 |
| Term deposit | 0 | 789,075 | 1,032,886 | 1,297,426 |
| Total non-current liabilities | 224,078 | 1,191,097 | 1,658,520 | 2,106,725 |
| Current assets | | | | |
| Inventories | 57,272 | 119,244 | 166,542 | 169,388 |
| Prepayments, other receivables and other current assets | 37,616 | 81,025 | 38,588 | 38,523 |
| Trade receivables | 446 | 1,014 | 1,182 | 1,837 |
| Financial assets at fair value through profit or loss | 10,515 | 110,229 | 68,744 | 138,553 |
| Term deposit | 0 | 0 | - | - |
| Cash and cash equivalents | 1,500,000 | 545,140 | 355,546 | 498,861 |
| Restricted cash | 1,418,359 | 1,205,302 | 1,086,579 | 532,607 |
| Total current assets | 0 | 645 | - | - |
| Total assets | 3,024,208 | 2,062,599 | 1,717,181 | 1,379,769 |
| <i>RMB'000</i> | 3,248,286 | 3,253,696 | 3,375,701 | 3,486,494 |

| <i>RMB'000</i> | Year ended December 31 | | | Six months ended |
|---|------------------------|------------------|------------------|------------------|
| | 2021 | 2022 | 2023 | June 30 |
| | 2021 | 2022 | 2023 | 2024 |
| Non-current liabilities | | | | |
| Deferred revenue | 0 | 0 | 8,674 | 15,885 |
| Lease liabilities | 6,509 | 7,459 | 1,859 | 2,366 |
| Total non-current liabilities | 6,509 | 7,459 | 10,533 | 18,251 |
| Current liabilities | | | | |
| Trade and other payables | 86,307 | 126,652 | 233,886 | 238,922 |
| Current liabilities | 3,420 | 9,601 | 19,922 | 26,382 |
| Borrowings | 0 | 0 | 50,000 | 75,000 |
| Lease liabilities | 2,896 | 6,543 | 4,018 | 3,875 |
| Forward foreign exchange contract | 0 | 278 | 0 | 0 |
| Other current liabilities | 4,480 | 9,010 | 9,957 | 14,426 |
| Total current liabilities | 97,103 | 152,084 | 317,783 | 358,605 |
| Total liabilities | 103,612 | 159,543 | 328,316 | 376,856 |
| Equity attributable to equity holders of the Company | | | | |
| Share capital | 332,401 | 332,401 | 332,401 | 332,401 |
| Share premium | 2,270,033 | 2,270,033 | 2,270,033 | 2,265,109 |
| Other reserves | 841,007 | 928,685 | 1,014,452 | 999,770 |
| Treasury shares | -9,149 | -33,793 | -87,594 | -74,600 |
| Accumulated losses | -289,618 | -403,173 | -481,907 | -413,042 |
| Total equity | 3,144,674 | 3,094,153 | 3,047,385 | 3,109,638 |
| Total equity and liabilities | 3,248,286 | 3,253,696 | 3,375,701 | 3,486,494 |